CAGR (5mg)
CAGR Long-Acting Dual Amylin & Calcitonin Receptor Agonist (DACRA)
TECHNICAL SPECIFICATIONS
- Product Reference : CAGR — Long-Acting DACRA Research Compound
- Chemical Class : Lipidated synthetic amylin analogue (DACRA)
- Physical Format : Lyophilised powder — hermetically sealed research container
- Analytical Purity (recommended) : ≥98% by RP-HPLC
- Identity Confirmation : LC-MS — molecular weight and sequence confirmation per batch COA
- Reconstitution Buffer : Sterile aqueous buffer pH 4.5–6.0 (optimal for stability)
- Storage — Lyophilised : −20°C or below, desiccated, light-protected, hermetically sealed
- Storage — In Solution : −80°C; single-use research aliquots; avoid repeated freeze-thaw
- Regulatory Class : Research Use Only (RUO) — Not for administration to living organisms
- Endotoxin Screening : <1.0 EU/mg (LAL assay) — required for preclinical model research quality
- COA Requirement : Batch-specific: HPLC purity + LC-MS identity + lot number + stability data
Disclaimer : For Research Use Only (RUO). Not for human use.
Product Overview
Discovery and Scientific Background :
Amylin is a 37-amino acid peptide hormone co-secreted alongside insulin from pancreatic beta cells in direct response to nutrient intake. Its functions in satiety signaling, gastric motility modulation, and postprandial glucose handling have been studied since the 1980s (Cooper et al., 1987). [R2] Despite this pharmacological interest, clinical translation of native amylin was severely limited by its inherent chemical instability — specifically its propensity to form amyloid fibrils and its half-life of only seconds to minutes under physiological conditions.
Pramlintide (FDA-approved Symlin) partially addressed these challenges using rat amylin sequence substitutions that reduce fibrillation, but its short duration of action necessitates multiple daily research protocols — a practical limitation that drove investment in longer-acting analogues. [R3] The scientific case for improved amylin analogues strengthened when research demonstrated that amylin and GLP-1 receptor agonists suppress energy intake through anatomically distinct but complementary neuronal pathways — the foundation for additive-effect combination research strategies. [R11]
Cagrilintide (AM-833) emerged from a Novo Nordisk medicinal chemistry program as a structurally optimized, lipidated, long-acting DACRA. The design strategy, SAR data, and Phase 1 pharmacokinetic results were published in the Journal of Medicinal Chemistry in 2021 (Enni et al.), establishing the scientific foundation for Phase 2 and Phase 3 research programs.
DISCLAIMER:
- Products sold on our website are meant for scientific research purposes only, designed for in vitro testing and lab experimentation exclusively. These products are not intended to be used as foods, drugs or cosmetics, any sort of bodily introduction of the products into humans or animals is strictly prohibited.
- All the products you see on the website are being sold as a freeze dried powder, in a sealed sterile vial; and should be reconstituted.
The product’s label clearly states the amount of product a vial contains; some products are offered in different variations. - The products we are selling come in a sealed vial but require additional lab equipment for proper testing.
- Though we make sure packaging, label, seals and writing does not differ from the product photos you see on our website, there is a chance for a minimal deviation.
